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Summary Gut hormones that modulate the growth of normal pancreas may also modulate the growth of cancers originating from pancreas.
This study visualized and compared the receptors for cholecystokinin (CCK), bombesin (BBS), secretin and vasoactive intestinal peptide
(VIP) in tumour-free tissue sections of human pancreas (n =10) and pancreatic ductal adenocarcinomas (n=12) with storage phosphor
autoradiography using radioligands. CCK-B receptors, present in control pancreata, were not detected in any of the pancreatic cancers. BBS
receptors were visualized in control pancreata, but they were absent in 10 of 12 pancreatic cancers. In 5 of 12 pancreatic cancers, receptors
for secretin were visualized, while binding for secretin was present in all tumour-free pancreata. Conversely, no specific binding of VIP was
detected in control pancreata but was identified in 3 of 12 pancreatic cancer specimens. It is concluded that the expression of gut peptide
receptors in pancreatic cancer differs from that in tumour-free pancreas. Receptors for these peptides are present in only a minority of
pancreatic cancer specimens.
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Pancreatic cancer, with its unfavourable properties, remains a
challenge to surgical or chemical therapy. Along with the realiza-
tion that gut hormones not only regulate the secretion but also cell
proliferation and differentiation of the exocrine pancreas (Poston
et al, 1991; Longnecker, 1991), considerable attention has recently
been given to the possible hormone responsiveness of pancreatic
cancer.
Several studies have focused on the effects of peptides or the
status ofpeptide receptors on the pancreas ofanimal models. Rats
treated with azaserine (inducing the acinar cell tumour) and
hamsters treated with BOP [N-nitrosobis(2-oxopropyl)amine;
inducing the ductal cell neoplasm] are the most frequently used
experimental models to study pancreatic carcinogenesis
(Longnecker et al, 1993). Promotive effects of cholecystokinin
(CCK) on the growth ofpancreatic neoplasms and overexpression
of CCK receptors in pancreatic neoplastic lesions of azaserine-
treated rats have been reported by studies from our and other
groups (Douglas et al, 1989; Bell et al, 1992; Tang et al, 1995a). In
the BOP-hamster model, however, the effects of CCK on pancre-
atic carcinogenesis are rather inconsistent (Johnson et al, 1983;
Howatson et al, 1985; Meijers et al, 1990). In addition, the effects
of other peptides, such as bombesin (BBS), secretin and vasoac-
tive intestinal peptide (VIP), on the growth ofpancreatic cancer in
animal models are inconsistent and unclear (Townsend et al, 1981;
Poston et al, 1988; Edwards et al, 1989; Meijers et al, 1991, 1992).
In the animal models, receptors for BBS, secretin and VIP disap-
pear with the progress of pancreatic carcinogenesis (Tang et al,
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1995a, 1996). Although the information from the animal models is
helpful to understand thebiology ofpancreatic cancer, thediscrep-
ancy ofspecies unavoidably results in vast gaps in the knowledge
on human pancreatic cancer.
Human pancreatic adenocarcinoma cell lines are good models
for studying the hormone sensitivity of pancreatic cancer. So far,
the growth effects of regulatory peptides and the expression of
peptide receptors on human pancreatic cancer cell lines are still
controversial (Estival etal, 1983; Alexander etal, 1988; Poston etal,
1988; Liehr et al, 1990; Smith et al, 1991; Qin et al, 1994).
Information on the status of receptors for gut peptides in normal
human pancreas and pancreatic cancer is very limited. If human
pancreatic cancer is hormone dependent, it is essential to know
what alterations in the spectrum of gut peptide receptors are
present in human pancreatic tumours when compared with control
tissue ofhuman pancreas.
In the present study, the receptors for CCK, BBS, secretin and
VIP were visualized and compared in tumour-free tissue sections




Control samples of pancreatic tissue without tumour were
obtained at surgery from 10 patients (six men, four women) with
small adenocarcinomas of the ampullary region or pancreas. This
pancreatic tissue was separated from the tumour and was
confirmed by histological examination to be free ofcancer orlight
microscopic abnormalities. The average age of the patients was
50 ± 12 (mean ± s.d.) years. Twelve pancreatic cancers were
obtained at surgery from seven men and five women. The average
age ofthesepatients was 66± 13 (mean ± s.d.) years. Immediately
after resection, one part of normal pancreatic tissue or pancreatic
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cancer was used for histological examination, while the other part
was rapidly frozen at -80°C. All specimens of the tumours were
of well-differentiated ductal pancreatic cancers. Tissue sections
(14 jum) were cut at -20°C using a cryostat microtome, mounted
onto gelatin-coated slides and dried overnight at -80°C.
Preparation of radioligands
['251]Bolton-Hunter sulphated CCK-8 (['25I]BH-CCK-8) and
[1251]Tyr4-BBS with a specific activity of 2200 Ci mmol-' were
purchased from New England Nuclear, Boston, MA, USA.
Tyr-B-ala-secretin and VIP-28 were iodinated using the
Chloramine-T oxidation method. lodinated peptides were sepa-
rated from unincorporated iodide by gel filtration on a Sephadex
G25-F or G50-SF column pre-equilibrated with 0.1 N acetic acid
and 0.1% gelatin or 0.25 M ammonium hydrogen carbonate
(Schaffalitzky et al, 1976; Ensinck et al, 1989). The specific
activity of ['251]Tyr-B-ala-secretin ([125I]secretin) was about
2200 Ci mmol-' and thatof['251]VIP-28 was about4000 Ci mmol-'.
Binding of radioligands to tissue sections
Binding of various radioligands to pancreatic tissue sections was
essentially done according to Tang et al (1995a). In brief, sections
mounted on slides were air-dried for 30 min and preincubated in
50 mM Tris buffer, pH 6.5, containing 5 g l-1 bovine serum albumin
at 22°C for 20 min. Binding of ['251]BH-CCK-8, ['25I]Tyr-BBS,
['251]Tyr-B-Ala-secretin and ['251]VIP-28 to pancreatic tissue
sections was performed by incubating the sections at 22°C in
50 mM MES, 0.25 g 1-1 bacitracin, 4 mg 1-1 leupeptin, 2 mg 1-1
chymostatin, 130 mm sodium chloride, 7.7 mm potassium chlo-
ride, 5 mm magnesium chloride, 1 mM EGTA and 100 pM each
radioligand at pH 6.0, 6.5, 7.0 and 7.5 separately for 180 min.
Alternate slides were incubated with addition of 1 jiM ofthe corre-
sponding non-radioactive peptides to determine the extent of non-
specific binding. Specific bindings for CCK, BBS, secretin and
VIP were 85%, 75%, 68% and 70%, respectively, of total binding
in normal rat pancreas as positive control. The sections were
subsequently washed three times for 5 min at 4°C in 50 mm Tris
buffer containing 5 g l-1 bovine serum albumin.
Storage phosphor autoradiography studies
After incubation, the dried tissue sections and one slide containing
two dried drops of 10 jil of 100 pM labelled peptide for standard-
ization were placed in a storage phosphor cassette for 24 h at 22°C
(Tang et al, 1995b). The latent image stored in the storage phos-
phor screen was scanned by the Phosphorlmager and the data were
processed with ImageQuant software (Molecular Dynamics,
Sunnyvale, CA, USA). For standardization in the screen, the
average stored radiation energy from the two whole drops ofradio-
ligand was quantified and expressed as response value per fmol of
labelled peptide. With this standard as reference, response values
from incubated tissue sections could be converted to fmol of
labelled peptide per area. Besides some sections for binding
studies, serial tissue sections with a thickness of 14 jm were
homogenized for measurement of the protein content using the
Lowry method (Lowry et al, 1951). Because the area of the
sections labelled with radioligands could be determined by storage
phosphor autoradiography, the protein content in corresponding
sections could be expressed as mg per area in 14-,um-thick tissue
sections. Thus, the binding could be converted to fmol of radio-
ligand bound per mg protein (Tang et al, 1995b).
Determination of CCK receptor subtype
To determine the affinities of various CCK receptor agonists
(CCK-8, gastrin) and antagonists [devazepide (L364,718) and
L365,260, obtained from Merck Sharp & Dohme Research
Laboratory, Rahway, NJ, USA; lorglumide and CR 2093, gifts
from Rotta research laboratories, Milan, Italy] in normal pancreas,
dose-inhibition curves were made with the agents indicated
above under identical conditions. Binding parameters (Kd, dissoci-
ation constant) were determined for each binding site by using
a non-linear least-squares curve-fitting program (LIGAND)
(Munson et al, 1980).
RESULTS
Storage phosphor autoradiographs showed specific bindings of
['251]Tyr4-BBS and ['251]secretin to all tumour-free human
pancreata (Figure 1). With the data from these control pancreatic
tissue sections, the dose-inhibition curve was best fit by a one-site
model for BBS or secretin. The binding affinities (Kd) of BBS and
secretin in control pancreata were 0.5 ± 0.11 and 0.7 ± 0.2 nm
respectively. In contrast to tumour-free pancreatic tissue, only 2 of
12 and 5 of 12 pancreatic cancers expressed specific receptors for
BBS and secretin respectively. The specific binding amount of
labelled BBS or secretin to tissue section ofthe pancreatic cancers
that were receptor positive was similar to that found in control
pancreas (Figure 1 and Table 1). No VIP receptors were demon-
strable in tumour-free pancreatic tissue. However, VIP receptors
were visualized in 3 of 12 pancreatic cancers (Figure 1 and Table 1).
As shown in Table 2, coexistence ofBBS and secretin receptors in
pancreatic cancer was detected in only one case. In addition, the
pancreatic cancer in another case expressed both receptors for VIP
and secretin.
No CCK receptors were identified in pancreatic cancers
(Figure 1). However, specific binding of ['251]BH-CCK-8 was
diffusely distributed through the tissue sections of tumour-free
pancreata (Figure 1 and Table 1). CCK-8, gastrin, L365,260 and
CR 2093 were similarly potent in the competitive inhibition of
['25I]BH-CCK-8 binding (Figure 2). Although the CCK-A antago-
nists devazepide and lorglumide were able to replace the binding
of ['251]BH-CCK-8 at a concentration of 1 jiM, their affinities were
about 45-fold lower than that ofthe CCK-B antagonists, L365,260
and CR 2093 (Figure 2B).
DISCUSSION
This study showed that the spectrum of gut peptide receptors in
pancreatic adenocarcinoma is different from that in tumour-free
pancreas. Receptors for CCK were present in all specimens of
control pancreas, while no specific binding of labelled CCK was
found in pancreatic cancer. The coexistence of BBS and secretin
receptors was present in all tumour-free pancreata but in only one
ofpancreatic cancer specimens. The histological differentiation of
the pancreatic cancer that possessed both BBS and secretin recep-
tors did not differ from that of pancreatic cancers with receptors
forBBS or secretin alone or the cancers without receptors for BBS









Figure 1 Autoradiographs of total and non-specific binding for [125l]BH-CCK-8, [1251]Tyr4-BBS, [1251]VIP-28 and [1251]secretin in tumour-free pancreata of the
human and pancreatic cancer. Column T represents total binding and column N shows non-specific binding. Magnification - x 3
or secretin. The reason forthe variability in expression ofBBS and
secretin receptors in pancreatic cancers is unclear. VIP receptors
were present in one-fourth ofpancreatic cancers, but they were not
identified in any of the tumour-free pancreata. This result points
out that some pancreatic cancers are associated with an increased
VIP receptor expression in the tumours.
On the basis of the affinity for specific CCK antagonists, the
receptors for CCK in peripheral tissues can be classified into two
subtypes, CCK-A and CCK-B receptors. The CCK-B receptor is
identical to gastrin receptor (Wank et al, 1994). CCK-8 is a non-
selective ligand for both CCK-A and CCK-B receptors. In the
present study, similarly highpotencies ofinhibition ['251I]BH-CCK-8
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Table 1 The quantification of peptide bindings in tissue sections of normal pancreas and pancreatic cancer
Peptide bound (fmol mg-1 protein)
n CCK BBS VIP Secretin
Normal pancreas 10 0.78 +0.50 0.30 ± 0.03 0 0.40 ± 0.05
Pancreatic cancer 12 0 0.22 ± 0.06 (2) 0.20 ± 0.05 (3) 0.18 ± 0.07 (5)
0 (10) 0 (9) 0 (7)
Mean ± s.d. The numbers in parentheses are the numbers of cases. CCK, cholecystokinin; BBS, bombesin;
VIP, vasoactive intestinal peptide.
Table 2 The distribution of receptors for BBS, VIP and secretin in pancreatic
cancers of 12 cases
Results of autoradiography
Case no. BBS VIP Secretin
1 + - +
2 - - +
3 - - +
4 - + +
















ling by CCK-8 and gastrin-17-I indicated expression of CCK-
ceptors in human pancreas. Although the selective CCK-A
ptor antagonists devazepide and lorglumide inhibited binding
ibelled CCK in human pancreas at a concentration of 1 gM, the
ities were much lower than those of the selective CCK-B
ptor antagonists L365,260 and CR 2093. Thus, the CCK-B
ptor is predominant in human pancreas. The result that the
ran pancreas contains CCK-B receptors is consistent with a
ious in vitro investigation of a single case (Kumamoto et al,
)). The existence of a human pancreatic CCK-B receptor has
suggested by Northern blot analysis of transcripts prepared
i human pancreas, which showed hybridization with a brain
creceptor cDNA probe (Silvente-Poirot et al, 1993).
he relatively low affinities ofdevazepide and lorglumide in the
ent radioligand inhibition study indicate the predominance of
C-B receptors in the exocrine component of the human
,reas. This finding does not support the implication of in vivo
ies (Malesci et al, 1990; Cantor et al, 1991) indicating that the
lation ofexocrine pancreatic enzyme secretion is mediated by
4-A receptors on acinar cells. Interestingly, the current views
eurohormonal regulation of pancreatic exocrine secretion in
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Figure 2 Dose-inhibition curves of ['251]BH-CCK-8 in tumour-free pancreas using unlabelled CCK-8, gastrin (A) and CCK-A antagonists (devazepide,
lorglumide) and CCK-B antagonists (L365,260, CR 2093) (B) in human pancreata. Ordinate, percentage of maximum binding (maximum binding is defined as
bound in absence of unlabelled CCK-8). Abscissa, concentrations of various agents indicated above. Each value is the mean + s.d. of three separate
experiments in which duplicate determinations were made
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rats suggest that the actions of gut hormones on the exocrine
pancreas in physiological conditions are mediated mainly viaeither
vagal sensory afferent or vagal efferent cholinergic pathways, or a
central vagal site (Chey et al, 1995). The autoradiographic method
used in this study allows the identification of receptors on the
exocrine pancreas but not on the nerve endings. Therefore, we can
not exclude the possible localization ofCCK-A receptors on intra-
pancreatic neurons or nerve fibres ofthe human pancreas.
In adult laboratory animals, rat pancreatic acinar cells contain
only CCK-A receptors (Sankaran et al, 1980; Schrenck et al, 1988;
Williams et al, 1988; Bell et al, 1992). The receptors for CCK in
the exocrine pancreas ofguineapig ordog (Fourmy et al, 1987; Yu
et al, 1987, 1990) are heterogeneous and present both A and B
subtypes. The different characteristics of CCK receptors in
pancreata of human and rodent suggest important differences
between humans and laboratory animals. However, the predomi-
nance of CCK-B receptors is reported in calf pancreas (Meuth et
al, 1993). Therefore, the status of CCK receptor subtype in calf
pancreas is closest to that in the human pancreas.
CCK is trophic to the pancreas and stimulates proliferation of
rat acinar cell tumours, leading to the speculation that CCK is
involved in the development orgrowth ofhuman pancreatic ductal
cell cancer. However, stimulative, inhibitory or no effect of CCK
on the growth of human pancreatic cancer cell lines or human
pancreatic cancer xenografts in nude mice have been reported
(Upp et al, 1987; Smith et al, 1990; Nio et al, 1993). Although the
membrane fractions of some pancreatic cancer cell lines, such as
MIA PaCa-2, BxPC-3, Capan-1, MDA-Amp-7 and MDA-Panc-
28, expressed CCK-B receptors (Smith et al, 1994), no specific
CCK binding was detected in the membranes of other pancreatic
cancer cell lines (Singh et al, 1991). Moreover, specific CCK
binding in intact cells could not be demonstrated (Herrington and
Adrian, 1995). The current study shows an absence ofCCK recep-
tors in all the pancreatic cancers studied and therefore does not
support the theory of an important role of CCK in ductal pancre-
atic cancer in humans. This finding may explain the results of a
clinical trial that failed to demonstrate any impact of MK-329, a
CCK-A receptor antagonist, on tumourprogression, pain ornutrition
inpatients withadvancedpancreatic cancer(Abbruzzese etal, 1992).
Overexpression of CCK receptors in acinar pancreatic adeno-
carcinoma of azaserine-treated rats have been demonstrated (Bell
et al, 1992). In ductal pancreatic adenocarcinoma of BOP-treated
hamsters, however, an absence of CCK receptors was reported in
our recent investigation (Tang et al, 1996). The present study also
showed that CCK receptors, consistently present in the tumour-
free human pancreas, are not detectable in ductal pancreatic cancer
of human. The different histogenesis of pancreatic cancer in rat
compared with human and hamster may be responsible for the
contrasting results.
The finding that human tumour-free pancreas contained BBS
receptors is consistent with a previous in vitro investigation of a
single case (Scemama et al, 1986) and provides the molecular
basis for the trophic effect ofBBS on human pancreas. The role of
BBS on pancreatic cancer cell lines is controversial (Alexander et
al, 1988; Liehr et al, 1990; Qin et al, 1994). The comparison of
BBS receptors between tumour-free pancreas and pancreatic
cancer in the present study does not favour a direct action of BBS
on the growth ofpancreatic cancer.
Secretin receptors have been identified in human pancreatic
membranes (Robberecht et al, 1988). Recently, Jiang et al (1995)
reported molecular cloning and functional expression of a human
pancreatic secretin receptor. The current study also demonstrated
the presence of secretin receptors in the tissue sections of the
control human pancreas. However, less than halfofthe pancreatic
cancers in this study expressed secretin receptors. These variable
changes in the status of secretin receptors may help in the under-
standing of why one group showed no effect of secretin on cell
proliferation of pancreatic cancer (Liehr et al, 1990), whereas
another group identified secretin receptors in human pancreatic
cancer (Estival et al, 1981).
In humans, VIP is a secretin-like partial agonist of pancreatic
bicarbonate secretion. Data showing that VIP stimulates secretion
of insulin, glucagon and bicarbonate output in healthy human
subjects (Domschke et al, 1977; Fahrenkrug et al, 1987) indirectly
suggest the presence of VIP receptors in the human pancreas.
Moreover, mRNA for VIP receptors has been found in the human
pancreas (Adamou et al, 1995). However, demonstration of
receptor mRNA does not always reflect the presence of functional
receptors in the cell membrane. Furthermore, it is unclear whether
mRNA for VIP receptors in the human pancreas is localized in
acinarcells, ductalcells, isletcells ornerve fibres. Hitherto, a direct
measurementofreceptors forVIP on the various components ofthe
normal human pancreas has not been performed. The absence of
VIP receptors in the human exocrine pancreas in this study indi-
cates that further investigation on localization of VIP receptors in
nerve fibres of the human pancreas would be worthwhile to prove
the role ofthe nervous system in the gut hormone action.
Inpancreatic cancercell lines, such as PANC-1 and MIA PaCa-2,
neither specific binding nor effect ofVIP were detected (Poston et
al, 1988; Liehr et al, 1990). However, VIP receptors were identi-
fied in another human pancreatic cancer cell line and these recep-
tors were considered to be involved in modulation of the cAMP
response during cell proliferation (Estival et al, 1983). Moreover,
in vivo scanning with radioiodinated VIP has visualized tumour
masses in patients with pancreatic cancer (Virgolini et al, 1994).
The results ofthe present study are in agreement with the finding
that only some ductal pancreatic adenocarcinomas express VIP
receptors.
VIP and secretin are members of the same peptide family.
However, they do not share a single receptor when mediating cell
functions. Secretin receptors are defined as having a high affinity
for secretin and relatively low affinity for VIP. Similarly, the
affinity ofVIP to its receptors is much higher than that of secretin
(Laburthe et al, 1994). The lack of coexistence of bindings for
radioactive secretin and VIP in tumour-free pancreas and in most
pancreatic cancers in the current study may indicate thatthere is no
cross-competition between secretin and VIP binding to control or
tumour cell membrane receptors.
Although ductal adenocarcinomas of the pancreas constitute a
tumour entity, the variable expression of gut peptide receptors in
pancreatic cancer suggests biological heterogeneity. The present
findings may be important when designing strategies forhormonal
therapy ofpancreatic cancer.
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